GT 02287
Alternative Names: GT-02287Latest Information Update: 28 Oct 2025
At a glance
- Originator Gain Therapeutics
- Class Antidementias; Antineoplastics; Antiparkinsonians; Neuroprotectants; Pharmacological chaperones; Small molecules
- Mechanism of Action Galactosylceramidase modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
- Preclinical Alpha 1-antitrypsin deficiency; Globoid cell leukodystrophy; GM1 gangliosidosis; Solid tumours
- Research Dementia
- No development reported Gaucher's disease
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for preclinical development in Gaucher's-disease in USA (PO, Pill)
- 06 Oct 2025 Efficacy and pharmacokinetics data from a phase I trial in Parkinson's disease released by Gain Therapeutics
- 30 Jun 2025 Adverse events data from a phase Ib trial in Parkinson's disease released by Gain Therapeutics